COMPASS Pathways Reports Before Its FDA Timeline Becomes More Than a Projection

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

COMPASS Pathways typically reports earnings before market open, meaning Day 0 captures the first reaction session while Day +1 reflects follow-through trading.

COMPASS Pathways exhibits significant post-earnings volatility, with an average absolute Day 0 move of 10.06% and Day +1 follow-through averaging 3.97%. The most recent earnings on May 13, 2026, produced the largest reaction in the dataset—a 16.97% surge on Day 0 following the strong beat, though this was partially reversed with a 3.10% decline the following session. The stock has shown a tendency toward positive Day 0 reactions in five of the last eight reports, but the magnitude varies dramatically: from a 23.10% plunge in October 2024 to the recent 16.97% spike.

The Day 0 trading range averages 13.43%, indicating substantial intraday volatility regardless of direction, while Day +1 ranges average 9.26%, suggesting continued uncertainty as investors digest the results. Notably, the most recent quarter showed the highest Day 0 move but relatively modest Day +1 activity, suggesting the market quickly priced in the positive surprise. Investors should prepare for double-digit percentage swings on earnings day, with the direction heavily dependent on whether results beat or miss expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.16% ($1.87) for the August 21 expiration, which is significantly higher than the historical average Day 0 move of 10.06%. This elevated implied volatility of 101.49% suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting heightened uncertainty around clinical trial updates or cash burn guidance.

Part 3: What Analysts Are Saying

Analysts maintain overwhelmingly bullish sentiment on COMPASS Pathways, with 15 of 18 analysts rating the stock a Strong Buy, 1 Moderate Buy, and 2 Hold ratings. The average recommendation of 4.72 out of 5.00 reflects near-consensus optimism about the company's long-term prospects. The mean price target of $23.20 implies 113% upside from the current price of $10.90, with the high estimate of $70.00 suggesting some analysts see potential for more than 540% appreciation if clinical programs succeed.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 14 to 15. This upgrade activity suggests growing analyst confidence, possibly driven by the strong Q1 beat or positive developments in the Phase III program. The wide target range—from a low of $13.00 to a high of $70.00—reflects the binary nature of biotech investing, where clinical success could drive exponential returns while setbacks could limit upside.

The consensus view appears focused on COMPASS's position as a leader in psychedelic medicine rather than near-term financial performance, with analysts willing to look through continued losses toward potential regulatory approval and commercialization. The lack of any Sell ratings underscores the Street's conviction in the company's pipeline, though the two Hold ratings suggest some caution about valuation or execution risk at current levels.

Part 4: Technical Picture

COMPASS Pathways enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has weakened from 100% Buy one month ago to 64% Buy one week ago, and now stands at just 56% Buy. This steady decline in technical strength suggests momentum has faded significantly heading into the report, with the stock trading at $10.90 after pulling back from recent highs.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has stalled, with bulls and bears in balance
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive but lacks conviction
• Long-term (100% Buy): Strong buy signal reflects positive momentum in the longer-term trend, indicating the broader uptrend remains intact

Trend Characteristics: The trend is characterized by Average strength with the Weakest direction, suggesting the stock is in a consolidation phase with diminishing momentum as it approaches earnings.

The stock is trading below its 5-day ($11.20), 10-day ($11.66), 20-day ($12.52), and 50-day ($12.41) moving averages, indicating short-term weakness and a potential downtrend in the immediate term. However, CMPS remains above its 100-day ($9.88) and 200-day ($8.18) moving averages, confirming the longer-term uptrend is still intact despite recent softness.

Key resistance now sits at the 20-day moving average of $12.52, which the stock would need to reclaim to reverse the recent downtrend. Support appears at the 100-day moving average of $9.88, just below current levels. The technical setup is cautionary heading into earnings—while the long-term trend remains positive, the stock has lost short-term momentum and is trading below all near-term moving averages. The 17.16% expected move suggests the market is pricing in significant volatility, and a strong beat would be needed to reclaim the 20-day moving average and restore bullish momentum. Conversely, a miss could test the 100-day support and potentially trigger a deeper correction.